Details of the Drug Combination

General Information of Drug Combination (ID: DCDPLKW)

Drug Combination Name

LY03004 JZL195

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

LY03004 DME5TUR

JZL195 DMEOCKZ

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 24.43

Bliss Independence Score: 24.43

Loewe Additivity Score: 38.38

LHighest Single Agent (HSA) Score: 38.4

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of LY03004

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[2]

Indication(s) of JZL195

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[3]

JZL195 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Acyloxyacyl hydrolase (neutrophil)	TT2EJXQ	AOAH_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63.